Not so long ago, undergoing a total hip or knee replacement and recovery was a grueling and often painful ordeal. While these are still major surgeries, new techniques and technologies are redefining them — and improving people’s outcomes, explains Dr. Brandon Bukowski, an orthopedic surgeon at the Mayo Clinic Health System in Mankato.
Continue reading It’s a new era for knee replacements and other joint surgeriesCategory Archives: Health Care
UAE’s Medcare among first centres outside the US to offer new SMA treatment for patients over two years of age
The newly licensed intrathecal gene therapy, enhances life-changing treatment options for children and families affected by Spinal Muscular Atrophy
Dubai, UAE–22December 2025: Families who were previously informed that their children had outgrown the eligibility for SMA gene therapy or were deemed not the right weight, now have renewed hope. Medcare Royal Speciality Hospital in Al Qusais has become among the first centres outside the USA to offer a newly licensed intrathecal gene therapy for Spinal Muscular Atrophy (SMA).
This treatment can now be administered to SMA patients well into their childhood and beyond. Approved after a thorough global assessment for intrathecal use, this therapy is tailored for children, teenagers, and adults, effectively removing the weight restrictions that have historically hindered access to gene therapy for this rare neuromuscular disorder.The milestone solidifies the UAE’s position at the forefront of cutting-edge genetic medicine and brings new hope to thousands of families worldwide.
Continue reading UAE’s Medcare among first centres outside the US to offer new SMA treatment for patients over two years of ageMemorial Sloan Kettering Cancer Center Announces Major Advance in Lymphoma Treatment at ASH 2025
A new three-drug immunotherapy combination significantly improves outcomes for relapsed follicular lymphoma, offering a chemotherapy-free treatment option
DUBAI, RIYADH, DOHA,DECEMBER 22nd, 2025.Memorial Sloan Kettering Cancer Center (MSK), one of the world’s leading cancer treatment, education and research institutions, has released clinical trial resultsshowing that a new three-drug immunotherapy combination provides significantly better outcomes for people with relapsed follicular lymphoma.
Follicular lymphoma is a slow-growing form of non-Hodgkin lymphoma that can become more aggressive over time. Treatment often works well at first, but many people experience relapse, and options become more limited with each recurrence. The development is particularly relevant for the Middle East, where hematologic cancers such as lymphoma and leukemia rank among the most common cancers in several countries, including the UAE, Saudi Arabia, and Kuwait, and where many patients face repeated relapses and limited treatment options.
The international phase 3 trial findings were announced at the American Society of Hematology (ASH) Annual Meeting. The trialfound that adding the bispecific antibody epcoritamab (Epkinly®) to rituximab (Rituxan®) and lenalidomide (Revlimid®) produced far stronger results than the standard two-drug regimen. The three-drug combination reduced the risk of cancer progression or death by nearly 80%; more than 95% of patients saw their cancer shrink (vs. 79%), and 82% had no detectable disease (vs. 50%). After 16 months, 85% remained progression-free, compared with 40% on standard treatment.
Continue reading Memorial Sloan Kettering Cancer Center Announces Major Advance in Lymphoma Treatment at ASH 2025
Eczema and Flare-Ups Increase During UAE Winters, RAK Hospital Expert Advises on Care
RAK Hospital dermatologist explains why even mild winters can aggravate inflammatory skin conditions and how residents can protect their skin
18 December 2025; Ras Al Khaimah, UAE: Dermatologists across the UAE are reporting a seasonal rise in skin-related complaints as winter sets in, with flare-ups of inflammatory conditions such as eczema and psoriasis becoming increasingly common despite the country’s relatively mild temperatures.
Continue reading Eczema and Flare-Ups Increase During UAE Winters, RAK Hospital Expert Advises on Care
ELPEN establishes 1st MEA subsidiary to expand access to high quality medicines across the region
The company’s 1st MEA subsidiary positions it at the heart of one of the world’s fastest-growing healthcare regions, enhancing access to trusted, high-quality treatments.
Dubai, United Arab Emirates. 17 December 2025. Greek pharmaceuticals manufacturer, ELPEN, today announced the launch of its 1st MEA subsidiary in the United Arab Emirates. The move marks a major milestone in the company’s international expansion strategy and strengthens its long-term commitment to improving healthcare across the region.
With its new offices in the UAE, ELPEN’s MEA subsidiary will serve as the company’s regional strategic centre, enabling closer engagement with health authorities, clinicians, scientific communities, medical societies, and institutional partners across the region.
Theodore Tryfon, Co – Chief Executive Officer ELPEN Group mentioned: “ELPEN enters the UAE carrying a legacy of nearly six decades of Greek scientific innovation and reliable pharmaceutical manufacturing. By connecting this heritage with a nation investing decisively in world-class healthcare, we aim to build long-term collaborations that support patient access, research excellence and sustainable industry growth. As one of Greece’s most advanced pharmaceutical groups, we remain committed to high-quality production and strong R&D, ensuring that Greek medicines can serve as credible, innovation-driven partners to the UAE’s healthcare vision.”
With the region experiencing rising demand for safe, trusted, and high-quality medicines, the new subsidiary positions ELPEN to operate with greater agility, cultural understanding, and proximity to the needs of local healthcare systems. The company has appointed Mohammad Allakany as General Manager for Middle East and Africa, bringing decades of healthcare experience and a proven leadership track record. In his role, he will oversee ELPEN’s growth strategy and regional expansion across MEA.
Continue reading ELPEN establishes 1st MEA subsidiary to expand access to high quality medicines across the region
UAE News 24/7 